Patents Assigned to Centocor, Inc.
  • Patent number: 8361474
    Abstract: Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: January 29, 2013
    Assignee: Centocor, Inc.
    Inventors: Jin Lu, Thomas Nesspor, Bernard Scallon, Linda Snyder
  • Patent number: 8293882
    Abstract: Isolated anti-tissue factor antibodies, immunoglobulins, cleavage products and other specified portions and variants thereof having enhanced ADCC activity, as well as anti-tissue factor antibody compositions, encoding or complementary nucleic acids, vectors, host cells, compositions, formulations, devices, transgenic animals, transgenic plants, and methods of making and using thereof. The antibodies of the invention bind human tissue factor and demonstrate enhanced ADCC activity. Accordingly, the antibodies can be used in a variety of methods for diagnosing, treating, and/or preventing diseases involving tissue factor, where enhanced ADCC activity is desirable such as cancer.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: October 23, 2012
    Assignee: Centocor, Inc.
    Inventors: G. Mark Anderson, Bernard Scallon, Michael Naso, Ann Cai, Cam Ngo
  • Patent number: 8278415
    Abstract: Polypeptides comprising EGFR extracellular domains I-III capable of forming dimeric EGF-binding proteins are provided. The dimeric construct of the invention is useful in applications where high affinity EGF binding is desired and can be used to select agents capable of binding to native EGFR in the presence of EGF.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: October 2, 2012
    Assignee: Centocor, Inc.
    Inventors: Wang Bryan, Frank Shi, Juliane Mills
  • Patent number: 8277809
    Abstract: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF? antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: October 2, 2012
    Assignee: Centocor, Inc.
    Inventors: Peter Bugelski, Anuk Das, Donald E. Griswold, Bailin Liang, Li Li, Robert T. Sarisky, Xiaozhou Shang
  • Patent number: 8241899
    Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: August 14, 2012
    Assignee: Centocor, Inc.
    Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
  • Patent number: 8114964
    Abstract: The present invention relates to at least one novel anti-MCP-1 antibody, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: February 14, 2012
    Assignee: Centocor, Inc.
    Inventors: Anuk Das, Raymond Sweet, Ping Tsui, Michael Bardroff
  • Patent number: 8093068
    Abstract: Methods useful for human adapting non-human monoclonal antibodies are disclosed. The methods select candidate human antibody framework sequences from a human germline framework database.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: January 10, 2012
    Assignee: Centocor, Inc.
    Inventors: Shizhong Chen, Shanrong Zhao
  • Patent number: 8071103
    Abstract: The present invention relates to at least one improved human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: December 6, 2011
    Assignee: Centocor, Inc.
    Inventors: Karyn T. O'Neil, Kristen Picha
  • Patent number: 8071729
    Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: December 6, 2011
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
  • Patent number: 8071333
    Abstract: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: December 6, 2011
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, Linda Snyder, Mohit Trikha, Marian T. Nakada
  • Patent number: 8067191
    Abstract: Methods for detecting IL-16 biological activity, detecting modulation of IL-16 biological activity, and diagnosing the presence of or susceptibility of a subject to an IL-16-related disorder involve measuring and comparing the levels of RANTES proxy produced by eukaryotic cells, such as CD4+ and CD9+ cell lines, peripheral blood mononuclear cells, HuT-78 cells, and/or THP-1 cells.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: November 29, 2011
    Assignee: Centocor, Inc.
    Inventor: William G. Glass
  • Patent number: 8067003
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 29, 2011
    Assignees: Centocor, Inc., Applied Molecular Evolution, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Patent number: 8043616
    Abstract: Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: October 25, 2011
    Assignee: Centocor, Inc.
    Inventors: Glenn Mark Anderson, Robert Jordan, Kristen Picha
  • Publication number: 20110195063
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Application
    Filed: September 17, 2010
    Publication date: August 11, 2011
    Applicants: Centocor, Inc., New York University
    Inventors: Junming Le, Jan T. Vilcek, Peter E. Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel, David J. Shealy
  • Patent number: 7982007
    Abstract: Isolated polynucleotides encoding Cynomolgus monkey Toll-Like Receptor 3 (cynoTLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, methods and uses of these are disclosed.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: July 19, 2011
    Assignee: Centocor, Inc.
    Inventors: Heena Beck, Jill Carton
  • Patent number: 7955597
    Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: June 7, 2011
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha
  • Patent number: 7910101
    Abstract: Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: March 22, 2011
    Assignee: Centocor, Inc.
    Inventors: Mark Cunningham, Vedrana Stojanovic-Susulic, Karyn O'Neil, Chichi Huang, Jeffrey Luo
  • Patent number: 7875427
    Abstract: Compositions and methods are provided for measuring and determining biomarkers for IL-13.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: January 25, 2011
    Assignee: Centocor, Inc.
    Inventors: Farhat Syed, Chong C. Huang, Katherine Li, Guihua Liu, Xiaozhou Shang, Li Li
  • Patent number: 7833531
    Abstract: The present invention provides to at least one novel human GLP-1 receptor agonist, or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 receptor agonist, or specified portion or variant, GLP-1 receptor agonist, or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including the use of long acting GLP-1 receptor agonists to improve insulin sensitivity or lipid profiles in obesity and related therapeutic and/or diagnostic compositions, methods and devices.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 16, 2010
    Assignee: Centocor, Inc.
    Inventors: Karyn T. O'Neil, Kristen Picha, Vedrana Stojanovic-Susulic
  • Patent number: 7833786
    Abstract: The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 16, 2010
    Assignee: Centocor, Inc.
    Inventors: Jill Giles-Komar, David Knight, David Peritt, Mohit Trikha